[8] Changes in the blood pressure and pulse rate observed in the

[8] Changes in the blood pressure and pulse rate observed in the core[8] and extension[9] studies were typical of those seen in patients receiving stimulants. Acknowledgements and Disclosures The full text article[1]

from which this profile report was derived was reviewed by A.C. Childress, Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV, USA; J. Elia, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA. The manufacturer of the agent under review was also offered an opportunity to comment on the original article[1] during the peer review process; changes resulting from comments received were made on the basis of LCZ696 price scientific and editorial merit. The MK5108 manufacturer preparation of the original article and this profile report was not supported by any external funding. References 1. Keating GM. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents. CNS Drugs 2011; 25 (4): 333–42.CrossRefPubMed 2. Pliszka S. Practice parameter for the assessment and treatment of children and OSI-027 mw adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Jul; 46 (7): 894–921.CrossRefPubMed 3. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005 Jun 1; 57

(11): 1215–20.CrossRefPubMed 4. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year

prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996 Mar; 35 (3): 343–51.CrossRefPubMed 5. Noven Pharmaceuticals, Inc. Daytrana© (methylphenidate transdermal system): US prescribing information [online]. Available from URL: http://​www.​daytrana.​com/​downloads/​novenPI.​pdf [Accessed 2010 Nov 29] 6. Wilens TE, Boellner SW, López FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008 Jun; 47 (6): 700–8.CrossRefPubMed 7. Anderson VR, Scott LJ. Methylphenidate Sitaxentan transdermal system in attention-deficit hyperactivity disorder in children. Drugs 2006; 66 (8): 1117–26.CrossRefPubMed 8. Findling RL, Turnbow J, Burnside J, et al. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr 2010 Jul; 15 (7): 419–30. 9. Findling RL, Katic A, Rubin R, et al. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2010 Oct; 20 (5): 365–75.

Comments are closed.